AbbVie's Humira, or adalimumab, topped this list of last year's 20 best-selling drugs worldwide, based on publicly available figures. GlaxoSmithKline's Advair came in second, followed by Roche Holding's Rituxan, or rituximab. Rounding out the top 10 were Sanofi's Lantus, Roche's Herceptin, AstraZeneca's Crestor, Johnson & Johnson's Remicade, Roche's Avastin, Eli Lilly and Co.'s Cymbalta, and Sanofi and Bristol-Myers Squibb's Plavix.

Related Summaries